- Protein Name
- Soluble RET kinase fragment
- Gene Name
- RET
- Organism
-
Homo sapiens
- Function
- Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation upon binding with glial cell derived neurotrophic factor family ligands. Phosphorylates PTK2/FAK1. Regulates both cell death/survival balance and positional information. Required for the molecular mechanisms orchestration during intestine organogenesis; involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue. Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e.g. ITGB1 and ITGB3)-dependent manner. Involved in the development of the neural crest. Active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage. Acts as a dependence receptor; in the presence of the ligand GDNF in somatotrophs (within pituitary), promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF. Regulates nociceptor survival and size. Triggers the differentiation of rapidly adapting (RA) mechanoreceptors. Mediator of several diseases such as neuroendocrine cancers; these diseases are characterized by aberrant integrins-regulated cell migration.
| Site |
Maximum Consensus Site Population |
Minimum Consensus Site Population |
Median Consensus Site Population |
| MPP |
23 |
8 |
19.0 |
| DFG |
15 |
2 |
6.0 |
| PIF |
21 |
3 |
11.5 |
| DRS |
12 |
3 |
7.0 |
| EDI |
14 |
4 |
8.5 |
| MT3 |
18 |
1 |
5.5 |
| LBP |
5 |
2 |
4.0 |
| CMP |
10 |
10 |
10.0 |
| ATP |
21 |
6 |
12.0 |
| PDB ID |
Maximum Consensus Site Population |
| MPP site |
DFG site |
PIF site |
DRS site |
DEF site |
EDI site |
MT3 site |
AAS site |
LBP site |
CMP site |
PDIG site |
ATP site |
PMP site |
| Total Druggable Structures per Site |
9 |
0 |
5 |
0 |
0 |
0 |
1 |
0 |
0 |
0 |
0 |
2 |
0 |
|
2IVV
|
15 |
3 |
17 |
0 |
0 |
10 |
0 |
0 |
0 |
0 |
0 |
19 |
0 |
|
2X2M
|
23 |
3 |
15 |
4 |
0 |
7 |
18 |
0 |
3 |
0 |
0 |
14 |
0 |
|
2IVT
|
16 |
8 |
15 |
10 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
10 |
0 |
|
2X2L
|
19 |
0 |
18 |
0 |
0 |
0 |
0 |
0 |
4 |
0 |
0 |
9 |
0 |
|
2IVU
|
21 |
6 |
21 |
0 |
0 |
0 |
0 |
0 |
5 |
0 |
0 |
21 |
0 |
|
5AMN
|
17 |
0 |
19 |
0 |
0 |
0 |
0 |
0 |
0 |
10 |
0 |
14 |
0 |
|
4CKI
|
22 |
6 |
3 |
0 |
0 |
0 |
0 |
0 |
5 |
0 |
0 |
12 |
0 |
|
2X2K
|
19 |
6 |
6 |
12 |
0 |
14 |
0 |
0 |
0 |
0 |
0 |
12 |
0 |
|
AFP07949
|
0 |
15 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
4CKJ
|
23 |
0 |
0 |
0 |
0 |
5 |
1 |
0 |
2 |
0 |
0 |
7 |
0 |
|
2IVS
|
20 |
7 |
18 |
3 |
0 |
14 |
8 |
0 |
0 |
0 |
0 |
15 |
0 |